In a controlled, third-party in vitro study, LifeVantage Corporation’s proprietary P84 formula was shown to hold strong biological activity in cellular pathways linked to gut regulation, repair and restoration.

New results from a human clinical study revealed that LifeVantage Corporation’s MindBody GLP-1 System provides increased fat loss, improved cravings control and healthier body composition.

LifeVantage Corporation has extended its MindBody GLP-1 System into international markets. The system’s success in the US has been credited with the company’s recent 49% year-over-year increase in revenue during the second quarter of the fiscal year.

LifeVantage Corporation announced it has completed an international study of its MindBody GLP-1 System. The in vitro cell study used Enzyme-Linked Immunosorbent Assay (ELISA) to measure total GLP-1 production and used fluorescent microscopy to visualize outcomes.

LifeVantage Corporation announced the US launch of its patent-pending MindBody GLP-1 System. The dual-product system is intended to help consumers reduce their cravings and support sustainable weight management by balancing hunger hormones.